| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.024 | 0.4 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |